Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.

Takehiro TozukaSatoru KitazonoHiroaki SakamotoHiroshi YoshidaYoshiaki AminoShinya UematsuTakahiro YoshizawaTsukasa HasegawaRyo AriyasuKen UchiboriNoriko YanagitaniTakeshi HoraiMasahiro SeikeAkihiko GemmaMakoto Nishio

Published in: Thoracic cancer (2020)

Further studies on immunotherapy are needed for patients with active BMs.

Keyphrases

brain metastases
small cell lung cancer
combination therapy
clinical trial
case control